Form 4: Bicara Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., sold 12,500 shares of common stock on August 10, 2026 for $27.97 per share.
Summary
- Option exercise/conversion: acquired 12,500 Common Stock at $3.79 ($47,372) on August 10, 2026; holds 142,355 after (Direct).
- Open-market sale: disposed of 12,500 Common Stock at $27.97 ($349,591) on August 10, 2026; holds 129,855 after (Direct).
- Option exercise/conversion: disposed of 12,500 Stock Option (Right to Buy) on August 10, 2026; holds 26,336 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $349,591 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Ivan Hyep — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 12,500 | $4 | $47.4K | 142,355 |
| 2026-08-10 | Open-market sale | Common Stock | 12,500 | $28 | $349.6K | 129,855 |
| 2026-08-10 | Option exercise/conversion | Stock Option (Right to Buy) | 12,500 | — | — | 26,336 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (12,500 shares) |
| 2026-08-10 | Open-market sale (12,500 shares) |
| 2026-08-10 | Option exercise/conversion (12,500 shares) |
Keywords
insider transaction, Form 4, BCAX, Bicara Therapeutics Inc., bearish, Ivan Hyep
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.